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Abstract
The nuclear pore complex (NPC) is the sole mediator of bi-directional transport between the 
nucleus and cytoplasm. Nup358 is a metazoan-specific nucleoporin that localizes to the 
cytoplasmic filaments and provides several binding sites for the mobile nucleocytoplasmic 
transport machinery. Here we present the crystal structure of the C-terminal domain (CTD) of 
Nup358 at 1.75 Å resolution. The structure reveals that the CTD adopts a cyclophilin-like fold 
with a non-canonical active site configuration. We determined biochemically that the CTD 
possesses weak peptidyl-prolyl isomerase activity and show that the active site cavity mediates a 
weak association with the HIV-1 capsid protein, supporting its role in viral infection. Overall, the 
surface is evolutionarily conserved, suggesting that the CTD serves as a protein-protein interaction 
platform. However, we demonstrate that the CTD is dispensable for nuclear envelope localization 
of Nup358, suggesting that the CTD does not interact with other nucleoporins.
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Introduction
Nuclear pore complexes (NPCs) are large, proteinaceous transport organelles that perforate 
the nuclear envelope and are the sole mediator of bi-directional nucleocytoplasmic 
transport.1 The human NPC is composed of 34 distinct proteins – 31 soluble nucleoporins 
(nups) and 3 integral membrane proteins of the pore membrane domain (poms). Each NPC 
protein occurs in multiple copies to generate a highly symmetrical structure with about 
1,000 individual polypeptide chains and an estimated molecular mass of approximately 120 
MDa.1 Electron microscopy structures of the NPC have shown a doughnut-shaped 
symmetric core that is embedded in ~100 nm pores perforating the nuclear envelope. The 
symmetric NPC core is decorated with different nucleoporin subsets that form distinct 
filamentous structures protruding from the nucleoplasmic and cytoplasmic faces.1 On the 
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nucleoplasmic face, the filaments bundle into a basket-like structure and provide binding 
sites for various components of other macromolecular machineries that carry out diverse 
cellular processes at the nuclear envelope, including chromatin remodeling, transcription, 
and DNA repair.1 On the cytoplasmic face, the filaments are extended and reach far into the 
cytoplasm, providing binding sites for a plethora of transport complexes and the mRNA 
export machinery.1
In humans, the cytoplasmic filaments are primarily composed of three proteins: Nup88, 
Nup214/CAN, and Nup358/RANBP2 (referred to as Nup358 in the following text).1 
Nup358 is a unique component of the metazoan NPC and is the largest known nucleoporin, 
composed of 3,224 residues in humans.2,3 Nup358 can be divided into several domains: an 
N-terminal TPR domain, an α-helical region, four Ran-binding domains, eight tandem zinc 
fingers, a SUMO E3 ligase domain, and a C-terminal domain that displays sequence 
homology to cyclophilins (Fig. 1a).2,3 Thus far, only the SUMO E3 ligase domain, two Ran-
binding domains and the N-terminal TPR domain have been structurally characterized.4-7 
Nup358 provides key interaction sites for various components of the nucleocytoplasmic 
transport machinery including Ran, SUMOylated RanGAP1, the NXF1•p15 mRNA export 
heterodimer, and the export karyopherin CRM1.1,7 Aditionally, we have recently shown that 
the N-terminal domain binds to single-stranded RNA.8
Apart from its essential function in nucleocytoplasmic transport, Nup358 is involved in a 
many other important cellular processes. During mitosis, Nup358 localizes to kinetochores 
and facilitates spindle formation as well as chromosome congression and segregation.9,10 A 
striking link exists between the cytoplasmic filament nups, their binding partners, and 
neoplastic disease. The expression of Nup358 is upregulated in plasma cells from patients 
with multiple myeloma, and mutations and fusions of the Nup358 gene have been associated 
with inflammatory myofibroblastic tumors.11,12 Moreover, mutations in Nup358 have been 
linked to heightened susceptibility of otherwise healthy children to acute necrotizing 
encephalopathy following common viral infections such as influenza. 13 Recently, Nup358 
has also been implicated in the delivery and integration of the genomic material of HIV-1 to 
the genome of terminally differentiated non-dividing cells.14-17
In order to gain insight into structure and function of Nup358, we have determined the 
crystal structure of the C-terminal domain (CTD) at 1.75 Å resolution. Nup358CTD adopts a 
canonical cyclophilin fold, but displays substantial alterations of the active site cavity. 
Surprisingly, we find biochemically that the observed structural changes fail to render the 
enzyme inactive and that the active site cavity retains weak peptidyl-prolyl isomerase 
activity. Moreover, we demonstrate that the active site cavity also facilitates binding to the 
HIV-1 capsid protein, as previously shown for cyclophilin A. In addition to the active site 
cavity, Nup358CTD features three extensive evolutionarily conserved surface patches, 
suggesting that the domain also functions as a protein-protein interaction platform. However, 
we determined by immunofluorescence microscopy that the CTD is dispensable for nuclear 
envelope localization of Nup358 in vivo, suggesting that it does not interact with other 
nucleoporins. Together, these data suggest that Nup358CTD is exposed at the tips of the 
cytoplasmic filaments of the NPC to facilitate binding to physiological substrates and could 
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potentially be hijacked by the pre-integration complex of HIV-1 to facilitate nuclear import 
and genome delivery.
Results
Structure determination
Based on a sequence alignment between human Nup358 and cyclophilin A (CypA), we 
generated an expression construct encompassing residues 3062 to 3224 that we termed the 
Nup358 C-terminal domain (CTD). Nup358CTD is monomeric in solution as determined by 
multiangle light scattering coupled to size exclusion chromatography with a measured 
molecular mass of 17.9 kDa (theoretical 18.4 kDa) (Fig. S1). Nup358CTD crystallized in the 
monoclinic space group P21 with six molecules in the asymmetric unit. The structure of 
Nup358CTD was solved by molecular replacement and the final model was refined to 1.75 Å 
resolution with Rwork and Rfree values of 12.2 % and 15.8 %, respectively. For details of the 
data collection and refinement statistics see Table 1.
Structural overview
Overall, Nup358CTD is a globular domain with a diameter of approximately 30 Å. 
Nup358CTD displays the canonical cyclophilin fold of an 8-stranded β-barrel (β1 to β8) that 
is flanked on three sides by an α-helix (αA to αC), as first observed in CypA (Fig. 1b,c).18 
The core of the domain is extensively decorated by several long and well-ordered loops that 
generate a large surface area. An ~20 Å long and ~10 Å wide surface groove is formed at the 
intersection between β-strands β3, β4, β5, and β6, the α-helix αB, and the loop linking β5 
and β6. This groove is utilized for substrate binding and catalysis in CypA and other 
cyclophilins.18
In order to identify surfaces of Nup358CTD that might be functionally important, we aligned 
sequences of Nup358CTD from a diverse set of species (Fig. S2), and mapped the sequence 
conservation onto the surface of Nup358CTD. A comparison of the conservation and 
electrostatic potential surfaces revealed that Nup358CTD possesses three evolutionarily 
conserved surface areas: (1) A groove in the surface that forms the active site in other 
cyclophilins, (2) an extensive hydrophobic patch on the back of the domain that is generated 
by hydrophobic substitutions which are not present in other cyclophilins, and (3) an acidic 
patch on the top of the domain (Fig. 2).
The active site of Nup358CTD
The 17 cyclophilin-like domains present in human proteins are very well conserved in both 
sequence and structure, especially at the active site, where there are only a handful of 
substitutions at residues that are catalytically important.19 In CypA, the model enzyme for 
studying cyclophilin peptidyl-prolyl isomerization activity, the active site cavity is generated 
by approximately fifteen residues, which in turn accommodate four to six residues of a 
linear peptide.18 The mechanism of peptidyl-prolyl isomerization by cyclophilins remains 
unclear, but there are several features that are conserved across family members. 
Hydrophobic residues form the bottom of the cavity that accommodates a substrate trans-
proline and several residues in the cavity form polar contacts with the peptide backbone of 
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the substrate peptide.19 Specifically, a critical arginine (Arg55 in CypA) that is invariant 
across cyclophilins forms key hydrogen bonds with the isomerized amide bond and the C-
terminal backbone carbonyl.19
Nup358CTD shares ~60 % sequence identity with human CypA and the crystal structures of 
CypA and Nup358CTD superimpose with a root-mean-square deviation of ~0.4 Å over 130 
Cα atoms (Fig. 3).20 Of the fifteen residues that contribute to the putative active site in 
Nup358CTD, nine are identical with their corresponding positions in CypA (Fig. 3). In 
particular, the residues that form the majority of the contacts between CypA and its 
substrates, His3186, Leu3182, Gln3171, and Phe3120, as well as the critical arginine, 
Arg3115, are conserved. However, other critical residues in the CypA active site that make 
key contacts with the substrate (Trp121, Phe113, Met61, and Ala103) are altered in the 
putative Nup358CTD active site (His3181, Val3173, Val3121, and Gln3163). Specifically, the 
imidazole ring of His3181 in Nup358CTD is still positioned to act as a hydrogen bond donor 
for the substrate backbone, analogous to Trp121 in CypA, but would be unable to form the 
additional hydrophobic contacts. Moreover, the substitutions of the bulky hydrophobic side 
chains Phe113 and Met61 for the smaller side chains Val3173 and Val3121 substantially 
reduce the extent to which Nup358CTD can form hydrophobic contacts with substrates, and 
the substitution of Gln3163 for Ala103 introduces a larger side chain where the substrate 
normally packs closely to the β-carbon of Ala103 (Fig. 3).
Our conservation analysis reveals that most of the putative Nup358CTD active site residues 
are nearly invariant across various vertebrates. However, whereas Nup358CTD possesses a 
cyclophilin-like fold, the putative active site of Nup358CTD displays marked differences 
from canonical cyclophilins, raising the possibility that Nup358CTD either has an altered 
peptidyl-prolyl isomerase substrate specificity or is catalytically inactive.
Catalytic activity
In order to determine whether Nup358CTD is an active peptidyl-prolyl isomerase, we used a 
chymotrypsin-coupled spectrophotometric assay on the isomerization of Suc-Ala-Ala-Pro-
Phe-2,4-difluoroanilide, a synthetic peptide that mimics CypA substrates.21 We found that 
Nup358CTD indeed possessed peptidyl-prolyl isomerase activity, but with a much lower 
efficiency than CypA. The Michaelis-Menten constants Km and kcat of Nup358CTD were 
determined to be 304.6 μM and 72 s−, compared to 309.9 μM and 119,913 s− for CypA, 
respectively (Fig. 4a,b).
To confirm that the weak enzymatic activity of Nup358CTD was in fact mediated by the 
putative active site, we generated the V3173W mutant that introduces the bulky aromatic 
residue tryptophan directly into the active site cavity. The behavior of the Nup358CTD 
V1373W on a gel filtration column was indistinguishable from that of the wild-type protein, 
indicating that the mutation did not affect proper protein folding. We found that the 
Nup358CTD V3173W mutant failed to accelerate cis/trans isomerization over the 
background rate (Fig. 4c), consistent with previous results that the analogous F113W 
mutation in CypA dramatically reduces enzymatic activity.22 Our data establish that 
Nup358CTD is indeed an active peptidyl-prolyl isomerase, but with substantially reduced 
enzymatic activity, supporting the results of our structural analysis of the active site cavity.
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HIV-1 capsid protein interaction
Interactions between cyclophilins and the HIV-1 capsid protein are a critical part of the viral 
life cycle. CypA binds to the HIV-1 capsid protein (HIV-1CA) and is specifically 
incorporated into the viral capsid, preventing Ref-1 mediated restriction of HIV-1 infection, 
and thus is essential for HIV-1 infectivity.23-25 The crystal structure of the CypA•HIV-1CA 
heterodimer revealed that CypA recognizes and binds a proline-rich loop of HIV-1CA with 
its active site (Fig. 5).26 Recent studies have proposed that Nup358 plays a role in the 
delivery and genomic integration of the genetic material of HIV-1 to the nucleus by 
facilitating an interaction to HIV-1CA via its C-terminal domain.15-17
To characterize the interaction between HIV-1CA and Nup358CTD, we employed a size 
exclusion chromatography binding assay. Whereas HIV-1CA and CypA formed a stable 
stoichiometric 1:1 complex (Fig. 6a), we found the interaction between HIV-1CA and 
Nup358CTD to be weaker (Fig. 6b). To determine whether the interaction was mediated by 
the Nup358CTD active site, we tested whether the V3173W mutant is capable for forming a 
complex with HIV-1CA. Strikingly, the weak interaction observed between Nup358CTD and 
HIV-1CA was completely abolished in the Nup358CTD V3173W mutant (Fig. 6c). To 
confirm the weak interaction detected by size exclusion chromatography, we additionally 
employed isothermal titration calorimetry. Although the interaction strength is at the limit 
for reliable quantification of thermodynamic parameters (Kd > 200), we were able to observe 
a significant interaction between Nup358CTD and HIV-1CA. In agreement with our size 
exclusion chromatography assay, we did not observe any interaction between Nup358CTD 
V3173W and HIV-1CA (Fig. S3).
The results of the isothermal titration calorimetry experiments are consistent with the 
relatively minor peak shift observed for the interaction between HIV-1CA and Nup358CTD 
compared to the shift observed for the complex formed by HIV-1CA and CypA. Thus, 
Nup358CTD binds the HIV-1 capsid protein with its active site, but it does so with a reduced 
binding affinity, consistent with the observed structural alterations of the active site.
In vivo localization assay
Nup358 localizes to kinetochores after the breakdown of the nuclear envelope, but it is a 
stable component of the cytoplasmic filaments during interphase.2,3,9 To determine whether 
Nup358CTD is involved in the attachment of Nup358 to NPCs, we performed a series of 
immunofluorescence localization experiments in HEK293 cells. Both the HA-tagged full-
length Nup358 and a C-terminal truncation that lacks the CTD (Nup358ΔCTD) yielded 
nuclear envelope rim staining that coincides with staining by mAb414, an antibody that 
recognizes a group of phenylalanine-glycine (FG)-repeat-containing nucleoporins at the 
nuclear rim.27 In contrast, the staining of a construct containing only the HA-tagged 
Nup358CTD failed to enrich at the nuclear rim (Fig. 7). These data establish that the CTD is 
not required for nuclear envelope localization and dispensable for Nup358 anchoring to the 
cytoplasmic face of the NPC.
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Conclusions
We determined the crystal structure of the C-terminal domain of Nup358, a unique 
component of the metazoan NPC, and established biochemically that the domain possesses 
peptidyl-prolyl isomerase activity in addition to its previously described E3 ligase activity.28 
We show biochemically that Nup358CTD interacts with the HIV-1 capsid protein. 
Additionally, analysis of the evolutionary conservation of the Nup358CTD surface suggests 
that the domain also functions as a protein-protein interaction platform. However, it is 
unlikely that the physiological binding partners are other nucleoporins as Nup358CTD does 
not localize to the nuclear envelope and is dispensable for nuclear envelope localization of 
Nup358 in vivo.
Despite many years of research on cyclophilins, the precise catalytic mechanism by which 
these enzymes catalyze proline isomerization remains poorly understood. Deeper 
mechanistic insights remain elusive partly because of sequence variation within the active 
site and a lack of physiological substrates. The active site cavity of Nup358CTD displays 
similarity to those found in the cyclophilin-like domains of cyclophilin G and NK-tumor 
recognition protein, distinct from “classical” cyclophilin active sites.29 Further experiments 
with this subset of cyclophilins are required to see whether their distinct active site 
configuration recognizes a unique set of substrates.
What role could a peptidyl-prolyl isomerase have at the periphery of the NPC? Besides a 
role in protein folding, peptidyl-prolyl isomerases also participate in a wide range of 
signaling pathways and Nup358CTD may act in a similar way on an unknown substrate. 
Alternatively, it is possible that Nup358CTD may also function as a protein-protein 
interaction module at the tips of the cytoplasmic filaments, perhaps serving as a surveillance 
domain to attract cargo molecules far away from the transport channel of the NPC. We 
speculate that this functionality may also serve to specifically recognize a thus unknown 
binding partner, leading to increased concentration at the cytoplasmic face of the NPC, 
similar to the Ran-binding domains of Nup358. Given the increased local concentration of 
Nup358 that is generated by its localization to the NPC, even relatively weak interactions 
may play physiogically important roles. Viral proteins such as the HIV-1 capsid protein may 
hijack such functionality to facilitate their nuclear import potentially by promoting 
uncoating or interactions with transport machinery as suggested previously.17 Our studies 
provide a structural and biochemical platform to dissect these interactions.
Methods
Protein expression and purification
DNA fragments encoding residues 3062-3224 from human Nup358, residues 1-165 of 
human Cyclophilin A, and residues 1-146 of the HIV-1 capsid protein were cloned into a 
modified pET28a vector, containing an N-terminal hexahistidine-tag followed by a 
PreScission protease cleavage site using NdeI and NotI restriction sites.30 Nup358CTD 
V3173W was generated by site directed mutagenesis and confirmed by DNA sequencing.
All proteins were expressed in E. coli BL21-CodonPlus(DE3)-RIL cells (Stratagene) in LB 
media. Expression was induced at an OD600 of approximately 0.6 with 0.5 mM IPTG at 
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18 °C for 16 hours. Cells were harvested by centrifugation and resuspended in a buffer 
containing 25 mM TRIS, pH 8.0, 500 mM NaCl, 20 mM imidazole, 5 mM β-
mercaptoethanol (β-ME) and complete EDTA-free protease inhibitor cocktail (Roche).
For purification, the cells were lysed with a cell disruptor (Avestin) and DNAse I (Roche) 
was added to the lysate before centrifugation at 30,000 x g for 1 hour. The supernatant was 
filtered with a 0.45 μm filter (Millipore) and loaded onto a Ni-NTA column (GE Healthcare) 
equilibrated in buffer A (20 mM TRIS, pH 8.0, 500 mM NaCl, 20 mM imidazole, and 5 mM 
β-ME). Protein was eluted with a linear gradient of buffer B (20 mM TRIS, pH 8.0, 500 mM 
NaCl, 500 mM imidazole, and 5 mM β-ME). Fractions were pooled and loaded onto a 
HiPrep Desalting column (GE Healthcare) equilibrated in 20 mM TRIS, pH 8.0, 100 mM 
NaCl, and 5 mM β-ME. PreScission protease was added to the eluate and the protein was 
cleaved at 4 °C for 16 hours. Digested protein was loaded onto a Ni-NTA column and 
collected in the flowthrough, concentrated in a centrifugal filter (Millipore), and loaded on a 
Superdex 75 16/60 column (GE Healthcare) equilibrated in buffer containing 20 mM TRIS, 
pH 8.0, 100 mM NaCl, and 10 mM DTT. Protein-containing fractions were pooled and 
concentrated to 65 mg/ml for crystallization studies and 30 mg/ml for biochemistry studies.
Protein crystallization and data collection
Protein crystallization was carried out at 21 °C in hanging drops consisting of 1.0 μl protein 
solution and 1.0 μl reservoir solution. Crystals were grown in 0.1 M TRIS-HCl, pH 8.3, 0.2 
M NaCl, and 0.9 M K/Na tartrate with a protein concentration of 65 mg/ml. Crystals were 
cryoprotected in the reservoir solution supplemented with 20 % glycerol and flash frozen in 
liquid nitrogen. X-ray diffraction data was collected at 100 K at Beamline 12-2 at the 
Stanford Synchrotron Radiation Lightsource (SSRL).
Structure determination and refinement
X-ray diffraction data was processed with the HKL-2000 denzo/scalepack package. A model 
of human Cyclophilin A, PDB code 19MC was used as a search model for molecular 
replacement with Phaser.20,31 Subsequent model building and refinement using anisotropic 
B-factors were performed with Coot and PHENIX, respectively.32,33 The final model 
contains residues 3,062 to 3,224 and was refined to 1.75 Å resolution with Rwork and Rfree 
values of 12.2 % and 15.8 %, respectively. The stereochemical quality of the model was 
assessed with PROCHECK and MolProbity.34,35 For details of the data collection and 
refinement statistics see Table 1.
Kinetic analysis
Enzyme kinetics were analyzed following a previously established chymotrypsin-coupled 
spectrophotometric assay.21 Peptidyl-prolyl isomerase activity was measured with a 
spectrophotometer (Shimadzu) at 9 °C using the cleavage of Suc-Ala-Ala-Pro-Phe-2,4-
difluoroanilide (Bachem), which led to an increase of absorbance at 290 nm. CypA and 
Nup358CTD were assayed at final concentrations of 20 nM and 2 μM, respectively. The final 
concentration of α-chymotrypsin (Sigma) was 150 μg/ml. Suc-Ala-Ala-Pro-Phe-2,4-
difluoroanilide (Bachem) was dissolved in a solution of Tetrafluoroethylene (TFE) and 500 
mM LiCl and the reaction was started by the addition of Suc-Ala-Ala-Pro-Phe-2,4-
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difluoroanilide to the cuvette for final concentrations that ranged from 50 μM to 500 μM. 
The reaction was carried out in 20 mM TRIS, pH 8.0, 100 mM NaCl, and 5 mM β-ME.
Analytical size-exclusion chromatography
HIV-1CA was mixed in approximately equimolar amounts with Nup358CTD, Nup358CTD, or 
CypA and incubated on ice for approximately 30 minutes before injection onto a Superdex 
75 10/300 GL gel-filtration column (GE Healthcare) equilibrated in 20 mM TRIS, pH 8.0, 
100 mM NaCl, and 5 mM β-ME. Complex formation was monitored by the shift of the 
respective protein peaks in the chromatogram and by SDS-PAGE of the protein-containing 
fractions.
ITC measurements
ITC measurements were performed at 23 °C using an ITC200 calorimeter (GE Healthcare). 
Protein samples were stored in a buffer containing 20 mM TRIS, pH 8.0, 100 mM NaCl, and 
4 mM β-ME. To perform the titration, 2.5 μL of 3.7 mM HIV-1CA was injected into 200 μL 
of 350 μM Nup358CTD or 310 μM Nup358CTD V3173W every 240 s. The heat generated 
from dilution was subtracted for baseline correction. Baseline corrected data were analyzed 
with Origin 7.0 software with MicroCal add-ons. All experiments were performed at least 
three times.
Immunofluorescence microscopy
For immunofluorescence, Nup358 and Nup358 fragments (residues 1-3224, 1-145, and 
146-3224) were inserted into the pCMV-HA vector (Clontech) using SalI and NotI 
restriction sites. The resulting Nup358 fragments contain an N-terminal HA-tag. HEK293T 
cells were grown on poly-L-lysine coated slides (Sigma) until ~50 % confluency. 
Transfection was performed with TransIT-LT1 transfection reagent (Mirus) according to the 
manufacturer's instructions. After 48 hours, the medium was removed and cells were washed 
in phosphate buffered saline (PBS) and fixed in PBS, supplemented with 2 % (w/v) 
formaldehyde for 5 min at room temperature. After two washes with PBS, the cells were 
permeabilized with PBS containing 0.1 % (v/v) TritonX-100 (Sigma-Aldrich) for 10 minutes 
at room temperature. The cells were then washed in PBS and blocked in PBS, supplemented 
with 10 % (v/v) Fetal Calf Serum (FCS) for 20 min at room temperature. For nuclear 
envelope staining, the cells were incubated with a 1:500 dilution of the monoclonal antibody 
mAb414 (Abcam) in PBS buffer, supplemented with 0.1 % (w/v) saponin and 10 % (v/v) 
FCS for 16 hours at 4 °C. Secondary antibody incubation was performed with a 1:3000 
dilution of Alexa Fluor 568 goat anti mouse (Invitrogen) in PBS, supplemented with 0.1 % 
(w/v) saponin and 10 % (v/v) FCS for 1 hour at room temperature, followed by three washes 
with PBS. For detection of the HA-tagged proteins, the cells were incubated with a 
monoclonal antibody anti-HA Fluor488 conjugate antibody (Invitrogen) for 1 hour at room 
temperature, washed three times with PBS, and mounted onto coverslips with ProLong Gold 
Antifade reagent with DAPI (Invitrogen). Slides were examined with an inverted 
fluorescence microscopy on a Carl Zeiss AxioImagerZ.1 equipped with a Hamamatzu 
camera.
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Illustration and figures
The sequence alignment of Nup358CTD was generated using ClustalX and colored with 
Alscript.36,37 The scientific illustrations were generated using PyMOL (Schrödinger, LLC; 
www.pymol.org), Igor (WaveMetrics), and Prism (GraphPad). The electrostatic potential 
was calculated with Adaptive Poisson-Boltzmann Solver (APBS).38
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
1. Crystal structure of the C-terminal domain of Nup358
2. Nup358 C-terminal domain has peptidyl-prolyl isomerase activity
3. Nup358 C-terminal domain has weak binding affinity for HIV-1 capsid 
protein
4. Nup358 C-terminal domain is dispensable for nuclear envelope 
localization
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Fig. 1. 
Domain organization and structure of Nup358CTD. (a) Domain organization of human 
Nup358. Domain boundaries are indicated by residue numbers. The bar above the domain 
structure denotes the crystallized fragment. I, II, III, and IV, Ran binding domains; NTD, N-
terminal domain; CTD, C-terminal domain; E3, E3 ligase domain. (b) Cartoon 
representation of Nup358CTD with a view rotated 180° along the vertical axis shown on the 
right. (c) Cartoon representation of Nup358CTD rotated 90° along the horizontal axis from 
above. (d) Representative 2|Fo|-|Fc| electron density map contoured at 1.5 σ.
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Fig. 2. 
Surface properties of Nup358CTD. (a) Surface representation of Nup358CTD, with the active 
site colored in red. (b) Surface representation colored according to sequence identity based 
on a multi-species sequence alignment (Fig. 2). The identity at each position is mapped onto 
the surface and is shaded in a color gradient from white (60 % less than 60 % identity) to red 
(100 % identity). (c) Surface representation colored according to electrostatic potential from 
-10 kBT/e (red) to +10 kBT/e (blue).
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Fig. 3. 
Comparison of Nup358CTD and Cyclophilin A active sites. (a) Detailed view of the 
Nup358CTD active site. (b) Detailed view of the Cyclophilin A active site (PDB Code 
1M9C). (c) Overlay of the active sites from Nup358CTD and Cyclophilin A. Critical active 
site residues are shown in stick representation, and the Cα-traces are shown in coil 
representation, according to the coloring scheme in A. The orientation of all active sites is 
identical.
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Fig. 4. 
Nup358CTD possesses peptidyl-prolyl isomerase activity. (a) Michaelis-Menten plot of the 
peptidyl-prolyl isomerization of Suc-Ala-Ala-Pro-Phe-2,4-difluoroanilide by Cyclophilin A, 
Nup358CTD, and Nup358CTD V3173W. (b) Michaelis-Menten plot of the peptidyl-prolyl 
isomerization of Suc-Ala-Ala-Pro-Phe-2,4-difluoroanilide by Nup358CTD and Nup358CTD 
V3173W. Note the different scale of the y-axis from panel (a). (c) Representative time-
course traces of the peptidyl-prolyl isomerization of Suc-Ala-Ala-Pro-Phe-2,4-
difluoroanilide by Cyclophilin A, Nup358CTD, Nup358CTD V3173W, and in the absence of 
an enzyme.
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Fig. 5. 
Structural comparison of Nup358CTD to the Cyclophilin A•HIV-1CA complex. The 
structure of Nup358CTD overlaid on the structure of the Cyclophilin A•HIV-1CA complex 
(PDB code 1M9C). The right panel is a close-up view of the interaction with the HIV-1CA 
loop rotated 90° along the vertical axis from the left panel. Note the clash between the 
Nup358CTD Q3163 and the HIV-1CA proline-rich loop.
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Fig. 6. 
Nup358CTD binds weakly to the HIV-1 capsid protein. (a-c) Size exclusion chromatography 
interaction analysis of HIV-1CA with (a) Cyclophilin A, (b) Nup358CTD, and (c) Nup358CTD 
V3173W. The analyzed fractions are indicated in gel-filtration profile by a grey bar. Notably, 
experiments were carried out with identical protein concentrations, the different peak height 
of the wild-type Nup358CTD is a result of a lower absorbance coefficient.
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Fig. 7. 
Nup358CTD is dispensable for nuclear envelope localization. Nup358CTD and Nup358 
fragments carrying a N-terminal HA-tag were transiently transfected into HEK293T cells 
and analyzed by fluorescence microscopy. HA-tagged Nup358 protein localization was 
detected with an α-HA antibody (green). The monoclonal α-mAb414 antibody (red) and 
DAPI (blue) were used as a reference for nuclear envelope and nucleus staining, 
respectively. The right panel shows the merged images.
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Table 1
Crystallographic Analysis
Data collection
Protein Nup358CTD
Synchrotron SSRL
Beamline BL12-2
Space group P21
Cell parameters
    a, b, c (Å) a=104.1, b=97.1, c=108.2
    α, β, γ (°) α=90.0 β=117.4 γ=90.0
Wavelength (Å) 0.9795
Resolution (Å) 50.0 – 1.75
Rsym (%)b 10.5 (98.5)
</> / <σ/>b 12.8 (2.3)
Completeness (%)b 97.7 (92.8)
No. observations 1,742,028
No. unique reflections 188,791 (17,824)
Redundancy 9.2 (7.7)
Refinement
Resolution (Å) 50.0 – 1.75
No. reflections total 188,714
No. reflections test set 9,500 (5.03%)
Rwork/ Rfree 12.2/ 15.8
No. atoms 17,190
    Protein 15,408
    Ligand 244
    Water 1,538
B-factors
    Protein 22.6
    Water 38.7
R.m.s. deviations
    Bond lengths (Å) 0.009
    Bond angles (°) 1.2
Ramachandran plotc
    Favored (%) 97.6
    Additionally allowed (%) 2.4
    Outliers (%) 0.0
MolProbity score 1.19
a SSRL, Stanford Synchrotron Radiation Lightsource
b
Highest-resolution shell is shown in parentheses
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cAs determined by MolProbity35
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